US › Healthcare

Seres Therapeutics Inc (MCRB)

US · Healthcare · Biotechnology

$4.10-2.61%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$736,000

Net profit

$4.6M

EPS

$-1.50

EPS estimate

$-2.07

Net margin

622.4%

EPS came in at -1.50 against a street estimate of -2.07 — a beat of 27.5%.

Key statistics

Market cap

$46.2M

Forward P/E

10.8

P/B

1.34

Book value

$3.51

EPS (TTM)

$-2.36

52-week high

$29.98

52-week low

$4.32

50-day MA

$5.15

200-day MA

$9.27

Beta

0.21

Analyst view

Analysts rate Seres Therapeutics Inc a buy (2 buy, 2 hold, 1 sell out of 5) with an average price target of $17.00.

Shareholding

Insiders

11.49%

Institutions

22.99%

Largest institutional holders

Fund	Stake
Flagship Ventures Management, Inc.	11.51%
Vanguard Capital Management, LLC	2.93%
Marshall Wace Asset Management Ltd	1.39%
Vontobel Holding Ltd.	1.22%
Susquehanna International Group, LLP	1.05%
BlackRock Inc	1.02%
Geode Capital Management, LLC	0.74%
Vanguard Fiduciary Trust Co	0.39%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Seres Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.